Adial Pharmaceuticals (ADIL) Competitors $0.39 -0.01 (-1.38%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.38 -0.01 (-2.92%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. HOTH, SYBX, LEXX, LPCN, BLRX, ASBP, MTEX, EDSA, ABP, and GELSShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Hoth Therapeutics (HOTH), Synlogic (SYBX), Lexaria Bioscience (LEXX), Lipocine (LPCN), BioLineRx (BLRX), Aspire Biopharma (ASBP), Mannatech (MTEX), Edesa Biotech (EDSA), Abpro (ABP), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Hoth Therapeutics Synlogic Lexaria Bioscience Lipocine BioLineRx Aspire Biopharma Mannatech Edesa Biotech Abpro Gelteq Adial Pharmaceuticals (NASDAQ:ADIL) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, ADIL or HOTH? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$13.20M-$1.46-0.27Hoth TherapeuticsN/AN/A-$8.19M-$1.07-1.21 Which has more risk & volatility, ADIL or HOTH? Adial Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Hoth Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Do insiders and institutionals believe in ADIL or HOTH? 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 4.3% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Hoth Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ADIL or HOTH more profitable? Hoth Therapeutics' return on equity of -114.32% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -209.89% -166.71% Hoth Therapeutics N/A -114.32%-105.92% Do analysts recommend ADIL or HOTH? Adial Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 1,927.88%. Hoth Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 210.08%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Adial Pharmaceuticals is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer ADIL or HOTH? In the previous week, Adial Pharmaceuticals had 5 more articles in the media than Hoth Therapeutics. MarketBeat recorded 9 mentions for Adial Pharmaceuticals and 4 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 1.47 beat Adial Pharmaceuticals' score of 0.55 indicating that Hoth Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHoth Therapeutics beats Adial Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.65M$137.64M$5.61B$9.84BDividend YieldN/A3.74%4.61%4.07%P/E Ratio-0.383.8130.2725.74Price / SalesN/A4,504.80469.95115.79Price / CashN/A13.1938.2159.48Price / Book0.6242.638.846.15Net Income-$13.20M-$90.99M$3.25B$265.06M7 Day Performance3.84%0.83%3.71%2.60%1 Month Performance7.20%4.42%5.85%2.83%1 Year Performance-59.29%184.02%30.25%25.58% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals2.6084 of 5 stars$0.39-1.4%$8.00+1,927.9%-59.1%$8.65MN/A-0.3820News CoverageEarnings ReportShort Interest ↑Gap DownHOTHHoth Therapeutics3.1245 of 5 stars$1.32-4.6%$4.00+204.0%+118.6%$17.38MN/A-1.154Earnings ReportShort Interest ↓SYBXSynlogic0.9621 of 5 stars$1.45+3.2%N/A+2.8%$16.91M$10K-0.5880Short Interest ↑Gap UpLEXXLexaria Bioscience3.8119 of 5 stars$0.86-2.0%$4.00+364.0%-75.1%$16.86M$460K-1.297News CoverageShort Interest ↓LPCNLipocine2.9126 of 5 stars$3.09+0.2%$9.00+191.7%-19.6%$16.51M$11.20M-3.0210News CoveragePositive NewsBLRXBioLineRx3.1611 of 5 stars$3.85-1.0%$26.00+575.3%-87.8%$16.40M$28.94M-0.4440News CoverageEarnings ReportGap DownASBPAspire BiopharmaN/A$0.33-8.1%N/AN/A$16.10MN/A0.00N/ANews CoverageEarnings ReportMTEXMannatech0.454 of 5 stars$8.31+3.9%N/A+40.2%$15.78M$117.87M-83.05250News CoverageEarnings ReportShort Interest ↑Gap DownEDSAEdesa Biotech2.1008 of 5 stars$2.24-0.9%$5.00+123.2%-49.7%$15.75MN/A-1.4120Earnings ReportShort Interest ↓ABPAbproN/A$0.26-6.9%$4.00+1,451.6%N/A$15.67M$180K0.0015Positive NewsEarnings ReportGap DownGELSGelteqN/A$1.64-1.3%N/AN/A$15.47M$100K0.00N/A Related Companies and Tools Related Companies Hoth Therapeutics Alternatives Synlogic Alternatives Lexaria Bioscience Alternatives Lipocine Alternatives BioLineRx Alternatives Aspire Biopharma Alternatives Mannatech Alternatives Edesa Biotech Alternatives Abpro Alternatives Gelteq Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access